Frances W. Grimstad

Frances W. Grimstad

Auto-generated profile, based on publicly available information

Frances W. Grimstad

Division of Gynecology, Department of Surgery, Boston Children’s Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
CKChance Krempasky
Chance Krempasky
MHMiles Harris
Miles Harris
LALauren Abern
Lauren Abern
FGFrances Grimstad
Frances Grimstad

1 March 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
FGFrances W. Grimstad
Frances W. Grimstad
KFKylie G. Fowler
Kylie G. Fowler
ENErika P. New
Erika P. New
CFCecile A. Ferrando
Cecile A. Ferrando
RPRobert R. Pollard
Robert R. Pollard
MGMeredith Gray
Meredith Gray

1 October 2021 in Journal of Pediatric and Adolescent Gynecology
Verified
Journal Article
Closed access
FGFrances Grimstad
Frances Grimstad
JKJessica Kremen
Jessica Kremen
JSJessica Shim
Jessica Shim
BCBrittany M. Charlton
Brittany M. Charlton
EBElizabeth R. Boskey
Elizabeth R. Boskey

20 July 2020 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
FGFrances W. Grimstad
Frances W. Grimstad
KFKylie G. Fowler
Kylie G. Fowler
ENErika P. New
Erika P. New
CFCecile A. Ferrando
Cecile A. Ferrando
RPRobert R. Pollard
Robert R. Pollard
VLVeronica Gomez Lobo
Veronica Gomez Lobo
Background: As transmasculine persons utilize androgen gender affirming hormone therapy as a part of transition, guidance has been lacking on the effects of the therapy on the ovaries, especially for those who may desire retention. Aim: To describe the ovarian histopathology of transmasculine persons on testosterone therapy following oophorectomy at the time of hysterectomy performed for gender affirmation. Methods: This was a multicenter case series study of transmasculine patients on testosterone therapy who underwent hysterectomy with oophorectomy for gender affirmation between January 2015 and December 2017 at 5 tertiary care referral centers. Patients were identified by their current procedural and International Classification of Diseases codes. Outcomes: Pre-, perioperative, and pathologic data were obtained from the electronic medical records and ovarian tissue descriptions from pathology reports were grouped into the following classifications: (i) simple/follicular cysts; (ii) polycystic ovaries; (iii) complex cysts; (iv) endometriomas; (v) other masses; (vi) atrophy; and (vii) normal. Results: 85 patients were included in the study. At the time of oophorectomy, the mean age and body mass index of the cohort were 30.4 ± 8.4 years and 30.2 ± 7.3 kg/m2, respectively, and the average interval from the initiation of testosterone to oophorectomy was 36 0.3 ± 37.9 months. On examination of ovarian histopathology, 49.4% (42) of specimens were found to have follicular/simple cysts, 5.9% (5) were polycystic, and 38.8% (33) had normal pathology. For those specimens with volume documented (n = 41), the median volume was 9.6 (range 1.5–82.5) cm3. There was no association between the duration of testosterone therapy or body mass index and the presence of cysts in the ovaries. Clinical Implications: The results of this study reported benign histopathology in ovaries of a large cohort of transmasculine persons on testosterone which should be included when counseling patients on ovarian retention, as transmasculine patients may choose to retain their ovaries while on testosterone for a variety of reasons (including no desire to undergo surgery, desire for backup sex steroids, and potential use for future fertility). Strengths & Limitations: This is a large multicenter study seeking to address the uncertainty in present counseling surrounding ovarian conservation in transmasculine persons on testosterone therapy. Its limitations included its retrospective nature and inability to address ovarian function after testosterone discontinuance. Conclusion: In this cohort of transmasculine patients on testosterone therapy undergoing hysterectomy with oophorectomy for gender affirmation, ovarian histopathology was benign in all the specimens.

1 September 2019 in RadioGraphics
Verified
Journal Article
Closed access
JSJustin T Stowell
Justin T Stowell
FGFrances W. Grimstad
Frances W. Grimstad
DKDaniel L. Kirkpatrick
Daniel L. Kirkpatrick
EBElizabeth R. Brown
Elizabeth R. Brown
RSRichard A. Santucci
Richard A. Santucci
KAKelli J. Andresen
Kelli J. Andresen
Understanding the various gender-affirming surgeries performed in transgender patients, the expected imaging appearance of the neoanatomy and of early and delayed complications, and the relevant im... Gender-affirming surgeries expand the options for physical transition among transgender patients, those whose gender identity is incongruent with the sex assigned to them at birth. Growing medical ...

12 May 2016 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
FGFrances Grimstad
Frances Grimstad
SKSacha Krieg
Sacha Krieg